These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31708657)

  • 1. Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.
    Ghashghaei M; Kucharczyk M; Elakshar S; Muanza T; Niazi T
    Curr Oncol; 2019 Oct; 26(5):e640-e650. PubMed ID: 31708657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Watanabe H; Nakane K; Takahara K; Naiki T; Yasui T; Shiroki R; Koie T; Miyake H
    Int J Urol; 2024 Sep; 31(9):986-993. PubMed ID: 38764245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
    Myint ZW; Momo HD; Otto DE; Yan D; Wang P; Kolesar JM
    JAMA Netw Open; 2020 Nov; 3(11):e2025826. PubMed ID: 33201234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD; Klaassen Z; Saad F
    Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
    Nevedomskaya E; Baumgart SJ; Haendler B
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.
    Afferi L; Longoni M; Moschini M; Gandaglia G; Morgans AK; Cathomas R; Mattei A; Breda A; Scarpa RM; Papalia R; de Nunzio C; Esperto F
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):173-182. PubMed ID: 37055663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
    BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 13. Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    Inoue T; Sasaki T; Kato M; Masui S; Nishikawa K
    BJU Int; 2021 Nov; 128(5):550. PubMed ID: 34333840
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
    Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
    J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to second-generation androgen receptor antagonists in prostate cancer.
    Schmidt KT; Huitema ADR; Chau CH; Figg WD
    Nat Rev Urol; 2021 Apr; 18(4):209-226. PubMed ID: 33742189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    González Del Alba A; Méndez-Vidal MJ; Vazquez S; Castro E; Climent MA; Gallardo E; Gonzalez-Billalabeitia E; Lorente D; Maroto JP; Arranz JA
    Clin Transl Oncol; 2021 May; 23(5):969-979. PubMed ID: 33625671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving options in metastatic castration-sensitive prostate cancer.
    Hamilou Z
    Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
    Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
    Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
    Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.